- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Immunostaining.
Displaying page 1 of 2.
EudraCT Number: 2022-003359-33 | Sponsor Protocol Number: MABS06 | Start Date*: 2023-06-21 | |||||||||||
Sponsor Name:MUMC | |||||||||||||
Full Title: Assess efficacy of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers | |||||||||||||
Medical condition: Mitochondrial myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001788-19 | Sponsor Protocol Number: ECS1479/2017 | Start Date*: 2018-08-24 |
Sponsor Name:Medical University Vienna | ||
Full Title: Metformin therapy to prohibit progression in patients with abdominal aortic aneurysm | ||
Medical condition: Abdominal aortic aneurysm | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001071-37 | Sponsor Protocol Number: LUC19-001 | Start Date*: 2019-08-06 |
Sponsor Name:Cliniques Universitaires Saint-Luc | ||
Full Title: Open label, phase II, Proof of Concept study of neoadjuvant celecoxib in newly diagnosed patients with endometrial carcinoma Acronym: Celebrido | ||
Medical condition: Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004223-36 | Sponsor Protocol Number: CFEM345EGB05 | Start Date*: 2005-07-29 |
Sponsor Name:South Manchester University Hospital | ||
Full Title: Short term biological study effects of Zoledronate and Letrozole on invasive breast cancer | ||
Medical condition: Breast Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001308-35 | Sponsor Protocol Number: EB-UGI 01 | Start Date*: 2006-05-04 |
Sponsor Name:The Finsen Center, Rigshospitalet | ||
Full Title: A phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal carcinomas, refractory or intolerable to standard systemic therapy | ||
Medical condition: Histologically or cytologically verified upper gastro-intestinal carcinoma, including carcinomas of the esophagus, cardia, stomac, pancreas, gall bladder, and bile ducts of the following histologic... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003774-40 | Sponsor Protocol Number: TheStopGISTtrial | Start Date*: 2016-11-09 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment | |||||||||||||
Medical condition: Gastrointestinal stromal tumour (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000117-31 | Sponsor Protocol Number: CAM-PLEX | Start Date*: 2015-03-03 | |||||||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | |||||||||||||||||||||||
Full Title: To assess the safety of continuous IV administration of the CXCR4 antagonist, plerixafor (Mozobil), at potentially active plasma concentrations and assess its impact on the immune microenvironment ... | |||||||||||||||||||||||
Medical condition: Pancreatic adenocarcinoma High grade serous ovarian adenocarcinoma Colorectal adenocarcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004239-35 | Sponsor Protocol Number: 2017/16 | Start Date*: 2019-09-26 | |||||||||||
Sponsor Name:Centre Antoine Lacassagne | |||||||||||||
Full Title: Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas | |||||||||||||
Medical condition: Soft tissue sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004554-42 | Sponsor Protocol Number: TAMDMD | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University of Basel Children's Hospital, Division of Neuropediatrics | |||||||||||||
Full Title: Tamoxifen in Duchenne muscular dystrophy: A multicenter, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Tamoxifen in Duchenne muscular dystrophy: A 48-week... | |||||||||||||
Medical condition: Duchenne muscular dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003212-22 | Sponsor Protocol Number: 10MI30 | Start Date*: 2013-06-03 | |||||||||||
Sponsor Name:GOSH/ICH Joint Research & Development Office | |||||||||||||
Full Title: Phase I study of ex-vivo lentiviral gene therapy for the inherited skin disease Netherton Syndrome | |||||||||||||
Medical condition: Netherton Syndrome (NS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000898-39 | Sponsor Protocol Number: SSGXXII | Start Date*: 2014-12-19 |
Sponsor Name:Scandinavian Sarcoma Group | ||
Full Title: Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study. | ||
Medical condition: gastrointestinal stromal tumor (GIST) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003585-27 | Sponsor Protocol Number: GNS561CLIQ0211 | Start Date*: 2018-01-11 | |||||||||||||||||||||||||||||||
Sponsor Name:GENOSCIENCE PHARMA | |||||||||||||||||||||||||||||||||
Full Title: Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary or secondary liver cancer | |||||||||||||||||||||||||||||||||
Medical condition: Hepatocellular carcinoma Intrahepatic cholangiocarcinoma Pancreatic adenocarcinoma with liver metastasis Colorectal cancer with liver metastasis | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003883-20 | Sponsor Protocol Number: CSTI571JDE74 | Start Date*: 2008-09-30 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection | |||||||||||||
Medical condition: gastrointestinal stromal tumors - adjuvant treatment after surgical tumor resection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Completed) SK (Completed) CZ (Completed) BE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000602-10 | Sponsor Protocol Number: SNT-III-012 | Start Date*: 2016-11-17 | |||||||||||
Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited | |||||||||||||
Full Title: A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and Tolerability of Idebenone in Patients with Duchenne Muscular Dystrophy Receiving Glucocorticoid Ste... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy (DMD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) FR (Completed) IT (Prematurely Ended) IE (Completed) HU (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000701-21 | Sponsor Protocol Number: CRAD001C2222 | Start Date*: 2004-11-25 |
Sponsor Name:Novartis Services AG | ||
Full Title: A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole (Femara®) as preoperative therapy of primary breast cancer in postmenop... | ||
Medical condition: Systemic treatment for breast cancer given when the primary tumors are still present in situ within the breast can result in large tumors being down-staged, which can allow for more conservative su... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003592-19 | Sponsor Protocol Number: NEOPAX-001 | Start Date*: 2012-12-11 |
Sponsor Name:CUB Erasme Hospital | ||
Full Title: Evaluation of tumoral perfusion modification by dynamic imaging after chemotherapy combining gemcitabine and nab-paclitaxel (Abraxane) in patients with potentially operable, locally advanced or met... | ||
Medical condition: Resectable (cohort 1) and locally advanced or metastatic (cohort 2) pancreatic ductal adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001853-15 | Sponsor Protocol Number: NL61830 | Start Date*: 2018-07-11 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: An explorative study for halting inflammation in patients with emphysema by intravenous administration of autologous bone marrow derived mesenchymal stromal cells. | ||
Medical condition: Pulmonary emphysema | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020305-32 | Sponsor Protocol Number: CRAD001CIT27T | Start Date*: 2010-08-06 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: A phase II, open label study to evaluate the activity and safety of Everolimus in association to Imatinib in PDGFRA-D842V unresectable or metastatic gastrointestinal stromal tumours (GISTs)as... | |||||||||||||
Medical condition: patients with unresectable and/or metastatic gastrointestinal stromal tumours with exon 18 PDGFRA mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001710-37 | Sponsor Protocol Number: NL73727 | Start Date*: 2021-05-26 |
Sponsor Name:Academisch Medisch Centrum | ||
Full Title: Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial. | ||
Medical condition: idiopathic inflammatory myopathies | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001267-33 | Sponsor Protocol Number: A6181107 | Start Date*: 2006-10-11 | |||||||||||
Sponsor Name:Pfizer Pharma GmbH | |||||||||||||
Full Title: Phase III Randomized, Multi Center Study of Sunitinib Malate (SU 011248) or Capecitabine in Subjects with Advanced Breast Cancer who failed both a taxane and an anthracycline chemotherapy regimen o... | |||||||||||||
Medical condition: Histologically or cytologically proven diagnosis of breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) GB (Completed) BG (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
